​

​Melanoma immunotherapy based on monoclonal antibodies has made attractive progress thanks to their high specificity of tumor-antigens. Non-IgG antibodies exhibit increasing potential in melanoma treatment in recent researches. With years of effort and powerful technology platform, Creative Biolabs now is capable to provide non-IgG antibodies services for melanoma target therapies to global customers.